Fighting for Lower Prescription Drug Prices and to Hold Drug Companies Accountable, Attorney General Jeff Landry Joins Lawsuit Targeting Major Generic Drug Companies for Price Fixing
BATON ROUGE, LA – Louisiana Attorney General Jeff Landry joined
Connecticut Attorney General William Tong and 42 other attorneys general in a
lawsuit against Teva Pharmaceuticals and 19 of the Nation's largest generic
drug manufacturers alleging a broad conspiracy to artificially inflate and
manipulate prices, reduce competition, and unreasonably restrain trade for more
than 100 different generic drugs.
The lawsuit, filed in U.S. District Court for the
District of Connecticut, also names 15 individual senior executive defendants
responsible for sales, marketing, pricing, and operations. The drugs at issue
account for billions of dollars of sales in the United States, and the alleged
schemes increased prices affecting the health insurance market, taxpayer-funded
healthcare programs like Medicare and Medicaid, and individuals who must pay artificially-inflated
prices for their prescriptions drugs.
“Louisiana patients rely on generic drugs every day and
they have felt the burn from the alleged conspiracy,” said General Landry. “I
am proud to join General Tong in these efforts to ensure those who have harmed
patients are brought to justice.”
Landry, Tong, and the others AG’s allege the drug
manufacturers engaged in a broad, coordinated, and systematic campaign to
conspire with each other to fix prices, allocate markets, and rig bids for more
than 100 different generic drugs. The drugs span all types, including tablets,
capsules, suspensions, creams, gels, ointments, and classes, including statins,
ace inhibitors, beta blockers, antibiotics, anti-depressants, contraceptives,
non-steroidal anti-inflammatory drugs, and treat a range of diseases and
conditions from basic infections to diabetes, cancer, epilepsy, multiple
sclerosis, HIV, ADHD, and more. In some instances, the coordinated price
increases were over 1,000 percent.
Their lawsuit seeks damages, civil penalties, and
actions by the court to restore competition to the generic drug market.